Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Asmita Chopra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5908-3993; OpenAlex author ID A5007444673. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2021: 7 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 3 papers

Papers 15

  1. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. First author DOI 10.1002/jso.70179↗
  2. Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Co-author DOI 10.1158/1078-0432.ccr-25-1110↗
  3. KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18633-7↗
  4. Survival prediction for CA19-9 non-producers with resected pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.05.007↗
  5. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
  6. ASO Author Reflections: Beyond CA19-9—Integrating Extracellular Vesicle (EV)–KRAS Dynamics into Neoadjuvant Therapy Assessment for Pancreatic Cancer First author DOI 10.1245/s10434-025-18770-z↗
  7. ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma Co-author DOI 10.1245/s10434-025-18842-0↗
  8. Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27856↗
  9. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26510↗
  10. Perioperative and oncologic outcomes of open, laparoscopic, and robotic distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1007/s13304-020-00927-y↗
  11. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/cji.0000000000000370↗
  12. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  13. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10175-y↗
  14. ASO Author Reflections: Impact of Neoadjuvant Therapy on Survival After Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10177-w↗
  15. Does neoadjuvant therapy improve survival in pancreatic adenocarcinoma? Co-author DOI 10.21037/hbsn-21-250↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Paniccia · 13 shared papers, 2021–2026 · strength 2.75
  2. Amer H. Zureikat · 12 shared papers, 2021–2026 · strength 2.24
  3. Aatur Dilip Singhi · 5 shared papers, 2021–2026 · strength 1.02
  4. Ibrahim Nassour · 5 shared papers, 2021–2026 · strength 0.95
  5. Siyang Zheng · 3 shared papers, 2025–2026 · strength 0.81
  6. Sebastiaan Ceuppens · 3 shared papers, 2025–2026 · strength 0.73
  7. Melissa Ellen Hogg · 4 shared papers, 2021–2026 · strength 0.67
  8. Herbert J. Zeh · 4 shared papers, 2021–2026 · strength 0.67
  9. Brian A. Boone · 4 shared papers, 2021–2026 · strength 0.65
  10. Joal D. Beane · 3 shared papers, 2021 · strength 0.53
  11. Michael T. Lotze · 3 shared papers, 2021–2026 · strength 0.49
  12. Anwaar Saeed · 2 shared papers, 2025–2026 · strength 0.44
  13. Anthony Gebran · 2 shared papers, 2024–2026 · strength 0.43
  14. Sarah B. Hays · 2 shared papers, 2025–2026 · strength 0.42
  15. Patricio Marcelo Polanco · 2 shared papers, 2025–2026 · strength 0.42
  16. Emile Farah · 2 shared papers, 2025–2026 · strength 0.42
  17. Mark S. Talamonti · 2 shared papers, 2025–2026 · strength 0.42
  18. Pranav Murthy · 2 shared papers, 2021–2026 · strength 0.38
  19. David L. Bartlett · 3 shared papers, 2021 · strength 0.36
  20. Nathan Bahary · 3 shared papers, 2021 · strength 0.36
  21. Sowmya Narayanan · 2 shared papers, 2021–2024 · strength 0.32
  22. Samer S. AlMasri · 2 shared papers, 2021–2024 · strength 0.32
  23. Caroline J. Rieser · 2 shared papers, 2021–2025 · strength 0.31
  24. Renee R. Anderko · 1 shared paper, 2026 · strength 0.26
  25. Jurgis Alvikas · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.